Providers/Grant Support
This activity is supported in part by an independent education grant from UroGen Pharma.
Credits Available
- Physicians — maximum of 2.0 AMA PRA Category 1 Credits™
- Nurses — 2.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is intended for Urologists, Urologic Oncologists, Medical Oncologists, Palliative Care, Pathologists, Advanced Practice Providers, Nurse Navigators and other healthcare professionals who treat patients with Intermediate-Risk Bladder Cancer.
Program Overview
This activity will cover the management of intermediate risk NMIBC, including diagnostic strategies, treatment advancements, BCG refractory cases, adjuvant therapies, with insights from leading experts in oncology and urology.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ strategies to enhance diagnostic accuracy for intermediate-risk bladder cancer, including applying risk stratification tools and integrating biomarkers into clinical workflows.
- Evaluate and implement alternative therapies to Bacillus Calmette-Guérin (BCG), including intravesical mitomycin, sustained-release formulations, and novel immunologic or gene therapies.
- Describe evidence-based surveillance protocols, balancing the need for disease monitoring with considerations of patient burden and healthcare costs.
- Understand the clinical utility of urinary biomarkers in predicting recurrence, guiding treatment selection, and monitoring treatment response in intermediate-risk bladder cancer.
- Recognize the importance of multidisciplinary care, fostering collaboration among urologists, oncologists, radiologists, and pathologists to optimize treatment planning and patient outcomes.
- Develop patient-centered treatment plans, tailoring therapy to individual clinical profiles while considering patient preferences and quality of life
Faculty
Dr. Kelly Bree
Dr. Kelly Bree is a urologic oncologist and Assistant Professor of Urology at MD Anderson Cancer Center in Houston, Texas.
Dr. Lindsey Herrel
Dr. Lindsey Herrel is a urologic oncologist practicing at the University of Michigan.
Dr. Amy Luckenbaugh
Dr. Amy Luckenbaugh is a urologist and an assistant professor in the Department of Urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Dr. Ruchika Talwar
Dr. Ruchika Talwar is a urologic oncologist at Vanderbilt University Medical Center in Nashville, Tennessee.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and BackTable. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosures of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Dr. Kelly Bree has no financial disclosures.
Dr. Lindsey Herrel has no financial disclosures.
Dr. Amy Luckenbaugh
- Consultant/Advisory Board: enGene
Dr. Ruchika Talwar
- Consultant/Advisory Board: ImmunityBio
The PIM planners and others have nothing to disclose. The Backtable planners and others have nothing to disclose.
All relevant financial relationships have been mitigated
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions please contact: grants@pimed.com